A 99mTc-labelled scFv antibody fragment that binds to prostate-specific membrane antigen by Nawaz, Saima et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1097/MNM.0000000000000698
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Nawaz, S., Mullen, G. E. D., Blower, P. J., & Ballinger, J. R. (2017). A 99mTc-labelled scFv antibody fragment
that binds to prostate-specific membrane antigen. Nuclear Medicine Communications. DOI:
10.1097/MNM.0000000000000698
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
A 99mTc-labelled scFv antibody fragment that binds to
prostate-specific membrane antigen
Saima Nawaza, Gregory E.D. Mullena, Philip J. Blowera and James R. Ballingerb
Introduction Prostate-specific membrane antigen (PSMA)
is an extensively studied antigen for imaging prostate
cancer. We prepared a single-chain variable fragment (scFv)
of J591, a monoclonal antibody that recognises an external
epitope of PSMA, incorporating a His-tag for labelling with
99mTc tricarbonyl, and evaluated its binding using human
PCa cell lines.
Methods J591(scFv) was expressed in HEK-293T cells and
purified by metal ion affinity chromatography, followed by
size exclusion chromatography. Stability and monomer/
dimer ratios of purified scFv under different storage
conditions were analysed by SDS-PAGE and analytical size
exclusion chromatography. J591(scFv) was labelled with
99mTc COð Þþ3 at 37°C for 60min. The stability of 99mTc-scFv in
human serum was analysed by SDS-PAGE with
autoradiography. Cell-binding studies were carried out
using PC3LN3 (PSMA negative) and PC3LN3-PSMA
(a variant engineered to express PSMA) cell lines.
Results J591(scFv) was most stable to dimerisation on
storage at − 80°C compared with − 20 and 4°C.
Radiochemical yields of 85–90% were obtained with the
final radiochemical purity of more than 99% after
purification by gel filtration. In these small-scale studies,
the maximum specific activity achieved was 7MBq/μg.
Liquid chromatography–mass spectrometry showed the
formation of 99mTc-J591(scFv), which was radiochemically
stable in serum, with no dissociation of 99mTc over 24 h.
Cell-binding assays showed specific binding to PSMA-
positive cells.
Conclusion J591(scFv) can be radiolabelled with
99mTc COð Þþ3 conveniently and efficiently. The labelled
product was stable in serum. It showed selective binding to
PSMA-positive cells compared with PSMA-negative cells.
This potential radiotracer warrants evaluation in PCa
xenograft models. Nucl Med Commun 00:000–000
Copyright © 2017 The Author(s). Published by Wolters
Kluwer Health, Inc.
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Introduction
The most extensively studied antigen in prostate cancer
(PCa) for antibody-based imaging is prostate-specific
membrane antigen (PSMA) [1]. Radiolabelled mono-
clonal antibodies (mAb) against PSMA have been used in
the clinic for the evaluation of PCa, primarily the
111In-labelled monoclonal antibody, capromab pendetide
(Prostascint), which has been commercially available
since 1997 for SPECT imaging [2]. Although the hybrid
technology of SPECT/CT has improved the accuracy of
111In-capromab imaging, capromab has the limitation that
it binds to an internal epitope of PSMA [3]. J591 is an
alternative antibody that recognises an extracellular
domain of PSMA and has been investigated for localisa-
tion and staging of PCa [4,5]. Indeed, there have been
recent reports of clinical trials with 111In-DOTA-J591 for
SPECT imaging, 89Zr-DFO-J591 for PET imaging and
177Lu-DOTA-J591 for therapy [6–8].
However, the biokinetics of mAb such as J591 are not
compatible with the use of short-lived radiolabels. For
example, optimal images with 111In-J591 were obtained
5–7 days after injection [6]. To improve upon the slow
kinetics of mAb, small molecule ligands for PSMA have
been investigated in recent years. Molecular Insight
Pharmaceuticals (now part of Progenics) have developed
a range of 99mTc and 123I-labelled PSMA ligands for
imaging and 131I-labelled analogues as potential targeted
therapeutic agents [9–11]. The first human results with
123I MIP-1072 and MIP-1095 show rapid accumulation
and prolonged retention in PSMA-expressing lesions,
with tumour/background ratios of ∼ 10 achieved in
SPECT images obtained 4 h after injection [9]. In
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parallel work, 68Ga-labelled urea-based PSMA inhibitors
have shown great promise for PSMA-specific tumour
imaging with PET [11,12] and analogues labelled with
177Lu are being evaluated for therapy [13]. Importantly,
given the 68-min half-life of 68Ga, diagnostic images can
be obtained within 60 min after injection [12].
The engineering of single-chain variable region frag-
ments (scFv, MWt: ∼ 27 kDa) of mAb is another route to
improve their kinetics for imaging with radionuclides
with short half-lives [14]. Parker et al. [15] described the
construction of a J591(scFv) based on the reported
complementarity determining region of J591. The
nucleotide sequence was optimised for expression in
Pichia pastoris and a hexa His-tag was added to facilitate
affinity purification. J591(scFv) has also been used as a
targeting agent for the delivery of toxins to PCa [16,17].
Antibody fragments such as scFv can be conveniently
labelled with 99mTc tricarbonyl through a His-tag. The
basis of 99mTc tricarbonyl kit formulation is disodium
boron carbonate, which serves as a CO source and a
reducing agent [18]. The group at the Paul Scherrer
Institute developed a direct labelling protocol for scFv
and minibodies carrying an N-terminal or a C-terminal
His-tag with 99mTc tricarbonyl [19] and further optimi-
sation has been performed by Badar et al. [20].
In an editorial on agents for imaging PCa, Eder et al. [11]
stated that PSMA is the most promising target because of its
accessibility on the cell surface, internalisation following
binding for retention of the radiolabel and correlation of
expression with stage and grade of PCa. With this objective,
we have developed a 99mTc-labelled scFv of the mAb J591
and evaluated its binding to PSMA-expressing human
PCa cells.
Materials and methods
Protein production and purification
The J591(scFv) sequence in the VH-VL orientation was
PCR amplified from the SFG P28z vector as described
previously [21]. Mammalian HEK-293T cells were used
to produce J591(scFv) in a growth medium of RPMI 1640
(PAA) with 10% FBS and antibiotics. The cells were
cultured in an atmosphere of 5% CO2 at 37°C. The
supernatant was collected over 4–6 weeks and stored at
4°C. When ∼ 1500 ml of supernatant had been collected,
it was purified by Ni-NTA chromatography (Qiagen,
Manchester, UK), followed by size exclusion FPLC
(AKTA, Superdex 75 10/300 GL; GE Life Sciences,
Little Chalfont, UK). The elution fractions were con-
centrated using centrifugal concentrators (Vivaspin 6
PES, MWCO 5000; Fisher-Sartorius, Loughborough,
UK) before exchanging the buffer to PBS (pH 7) by size
exclusion chromatography (as above). The protein was
analysed by SDS-PAGE (Novex, Fisher, Loughborough,
UK) using 12% gel, western blotting with 3,3-diamino-
benzidine peroxidase (Sigma-Aldrich, Gillingham, UK)
to detect the HRP-conjugated secondary antibody and
HPLC (SEC-2000; Phenomenex, Macclesfield, UK).
The protein was stored at − 80°C in small aliquots on the
basis of the protein concentration, which was determined
using a UV–visible Spectrophotometer Nanodrop 2000c
(Thermo Fisher Scientific, Paisley, UK). For stability
studies, aliquots were also stored at 4°C and − 20°C for
3 weeks. The effect of addition of 5% glycerol to reduce
the extent of dimerisation was also evaluated.
Radiochemistry
99mTc tricarbonyl was prepared by adding 1000MBq
99mTc-pertechnetate (Drytec generator; GE Healthcare,
Little Chalfont, UK) in 500 µl to an Isolink kit (donated by
Covidien Healthcare, Fareham, UK)) and heating it for
25min at 100°C. The formation of the 99mTc tricarbonyl was
monitored by TLC on glass-backed silica gel 60 plates
developed with 1% HCl in methanol [20]. The Rf values in
this system are as follows: 99mTc tricarbonyl, 0.2–0.8; 99mTc
colloids, 0.0 and 99mTc-pertechnetate, 0.9. An aliquot of the
99mTc tricarbonyl (∼200MBq in 100 µl) was then incubated
with 100 µl J591(scFv) (1 µg/µl) for 60min at 37°C. After
radiolabelling, the reaction mixture was applied to a size
exclusion column (Sephadex G-25 PD Mini-trap; GE Life
Sciences, Little Chalfont, UK), eluted with PBS and 30
fractions of 100 µl each were collected by gravity as described
previously [22]. The activity in the fractions was measured in
an ionisation chamber (CRC-15R; Capintec, Southern
Scientific, Henfield, UK). The fractions with the highest
activity (generally 8, 9 and 10) were analysed on iTLC-SA
strips (Agilent Technologies, Cheadle, UK) developed with
0.1mol/l citrate buffer pH 5.5 and analysed by a radio-
chromatogram scanner (BioScan, Washington DC, USA).
The Rf values in this system are as follows:
99mTc-J591
(scFv), 0.0; 99mTc tricarbonyl, 0.9 and 99mTc-pertechnetate,
0.9. The fractions with the highest activity were then pooled.
A series of experiments were conducted that involved
radiolabelling of J591(scFv) (10 µg) with different amounts
of 99mTc tricarbonyl (10, 30, 50 and 70MBq) to determine
the maximum amount of radioactivity that could be loaded
onto the J591(scFv). In another series, different con-
centrations of J591(scFv) ranging from 72 to 3.6 µmol/l
were reacted with the same amount of tricarbonyl (10 µl,
30MBq). Finally, J591(scFv) was radiolabelled with 99mTc
tricarbonyl in two different NaCl concentrations (140 and
500mmol/l) to determine the effect of salt concentration on
radiolabelling efficiency [20].
J591(scFv) and 99mTc-J591(scFv) were characterised by
mass spectrometry (MS) (Series 6520 QTOF LC–MS;
Agilent Technologies, Cheadle, UK). The unlabelled
scFv (20 µl, ∼ 30 µg) was analysed by direct injection and
99mTc-J591(scFv) (1MBq, 10 µl, ∼ 16 µg) was analysed
by liquid chromatography–mass spectrometry on a C18
column with an acetonitrile/0.1% formic acid gradient
from 0 to 100% acetonitrile over 15 min at a flow rate of
0.5 ml/min.
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Serum stability was studied by incubating 99mTc-J591
(scFv) with an equal volume of human serum at 37°C and
removing aliquots over the course of 24 h. Samples were tes-
ted for release of free pertechnetate or other small molecules
containing 99mTc by iTLC-SA as described above; however,
this method would not detect transchelation to serum proteins
as both 99mTc-J591(scFv) and serum proteins would remain at
the origin. Samples were analysed by SDS-PAGE 12% gel
with detection by a phosphorimager (Cyclone Plus; Perkin
Elmer, Beaconsfield, UK) and Coomassie blue staining.
Cell-binding studies
The PC3LN3 (parental, PSMA negative) and
PC3LN3-PSMA (a variant engineered to express PSMA)
cell lines were produced as described previously [22].
FACS Calibur (Becton Dickinson, Oxford, UK) analysis
before the cell-binding experiments with PCLN3 and
PC3LN3-PSMA cell lines confirmed PMSA status using
the anti-His-tag antibody penta-His Alexa 488 (Qiagen).
For cell-binding experiments, 24-well plates were seeded
with equal numbers of cells (4× 105) in a volume of
500 µl/well and maintained at 37°C for 24 h. To achieve a
range of protein concentrations, 10 serial dilutions of
99mTc-J591(scFv) were prepared in triplicate from
7200 nmol/l (10 µg in 50 µl) to 0.4 nmol/l (0.001 µg in 50 µl).
The cells were incubated with 99mTc-J591(scFv) for
60min at 4°C to minimise internalisation, after which the
supernatant was aspirated and the cells were carefully
washed three times with 500 µl Hanks’ balanced salt solu-
tion to remove any unbound radioactivity. The cells were
then lysed with 0.5mol/l NaOH (200 µl) and the lysate was
transferred to tubes for gamma counting (1470 Wallac
Wizard; Perkin Elmer). The percentage bound was plotted
against protein concentration and the results were analysed
by nonlinear regression using GraphPad Prism software
(San Diego, Califonia, USA) with a one-site total binding
algorithm to calculate an EC50 value for the cold mAb.
Statistical analysis
Results are expressed as mean ±SD for n independent
experiments. Differences between groups were assessed
using Student’s t-test for unpaired values.
Results
Protein production and purification
J591(scFv) was produced in mammalian cells. A yield of
10–12mg/l of J591(scFv) was obtained from the super-
natant after the purification steps of the Ni-NTA column
and SEC. In the Ni-NTA purification step, J591(scFv)
eluted as a single peak when the column was washed with
250mmol/l imidazole. In the SEC buffer adjustment step,
the dimer fraction eluted first (10–15ml), followed by the
monomer fraction (15–20ml) (Supplementary Fig. S1a,
Supplemental digital content 1, http://links.lww.com/NMC/
A116). An intense band observed at 27.7 kDa in both
SDS-PAGE (Supplementary Fig. S1b, Supplemental digi-
tal content 1, http://links.lww.com/NMC/A116) and western
blotting (Nawaz S, Kampmeier F, Mullen GED, Blower PJ
and Ballinger JR, unpublished data) also confirmed the
results. The purified sample was further analysed by size
exclusion HPLC. The monomer fraction eluted at 9min and
the dimer at 8min The problem of dimerisation over a period
of 3 weeks was minimised by immediate storage at −80°C
compared with 4°C and −20°C (Nawaz S, Kampmeier F,
Mullen GED, Blower PJ and Ballinger JR, unpublished
data). The addition of glycerol did not significantly decrease
the dimerisation of J591(scFv).
Radiochemistry
For the preparation of 99mTc tricarbonyl, pertechnetate
was added to the kit and heated for 25 min at 100°C.
TLC showed an 85–90% radiochemical yield of 99mTc
tricarbonyl, with the main impurity being free pertech-
netate. The product was used for the subsequent label-
ling reaction without purification.
Site-specific labelling with 99mTc tricarbonyl via the His-
tag of J591(scFv) resulted in a radiochemical yield of
85–100%. If the yield was less than quantitative, a final
radiochemical purity of more than 99% could be achieved
after a gel filtration purification step (Supplementary Fig. S2,
Supplemental digital content 1, http://links.lww.com/NMC/
A116). The radiochemical yield increased during incubation
at 37°C up to 60min, after which there was no further
increase. For higher concentrations of J591(scFv), the time of
incubation had no effect on the radiolabelling yield. However,
with low concentrations, the duration of incubation played an
important role (Fig. 1). For example, with 3.6 µmol/l J591
(scFv), the radiochemical yield increased from 27±2% at
30min to 80±5% at 60min (n=3, t-test, P=0.005), whereas
at 72 µmol/l, radiochemical yield was ∼100% at both time
points (P=NS). The maximum amount of 99mTc tricarbonyl
that could be loaded onto 1 µg J591(scFv) was 7MBq. As
previous work from this laboratory showed that the NaCl
concentration can influence labelling efficiency with 99mTc
Fig. 1
Effect of J591(scFv) concentration on labelling efficiency after 30 and
60min of incubation. Each value is mean+SD for three measurements.
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tricarbonyl [20], experiments were conducted at two different
salt concentrations. Increasing the NaCl concentration from
140 to 500mmol/l slightly, but not significantly, increased the
radiolabelling yield (Fig. 2). With 36 µmol/l J591(scFv), the
radiochemical yield after 60min of incubation was 75±4% at
140mmol/l NaCl and 85±5% at 500mmol/l NaCl (n=3, t-
test, P=NS). 99mTc-J591(scFv) was radiochemically stable in
serum, with no change in the speciation of 99mTc over 24 h as
shown by TLC and SDS-PAGE, where there remained only
an intense band at ∼30 kDa.
Analysis by MS following a direct injection of J591(scFv)
showed a strong peak at 27.7 kDa, which corresponds to
the molecular weight of the J591(scFv). Liquid
chromatography–mass spectrometry, using a C18 column,
showed the formation of 99mTc-J591(scFv) detected in
the radiometric chromatogram. MS of 99mTc-J591(scFv)
showed a single peak at 27.7 kDa.
Cell-binding studies
Before conducting the cell-binding experiments, both
the negative and the PSMA-positive cell lines were
analysed by FACS for PSMA expression. The
PC3LN3-PSMA cell line showed a positive shift in FL1,
whereas the parental PSMA-negative PC3LN3 showed
no shift in FL1. Serial dilutions of 99mTc-J591(scFv) were
incubated with the both cell lines at 4°C, to minimise
internalisation, for 60 min for binding equilibrium to be
reached. As can be seen in Fig. 3, the binding of
99mTc-J591(scFv) showed that J591(scFv) specifically
and saturably binds to the PC3LN3-PSMA cell line with
an EC50 value of 3.7 nmol/l, whereas only nonspecific
binding was observed in the PC3LN3 cell line.
Discussion
The role of molecular imaging in localisation and staging
of PCa is becoming increasingly important, with a variety
of probes under development [11]. Although recent
interest has focused on small molecules, there may be a
role for antibody-based targeting and the preparation of a
radiolabelled scFv fragment may offer a suitable balance
between binding affinity and pharmacokinetics suited to
short half-lives such as those of 99mTc or 68Ga.
J591(scFv) was conveniently produced in mammalian
cells at a moderate yield of 10–12 mg/l of J591(scFv).
Purification by an Ni-NTA column, followed by size
exclusion chromatography yielded the monomer, which
was characterised by SDS-PAGE, western blotting and
SEC. The product could be stored at − 80°C for at least
3 weeks with minimal dimerisation of J591(scFv).
Site-specific labelling of the His-tag of J591(scFv) was
performed by a two-step procedure. First, 99mTc tri-
carbonyl was prepared in a good yield by the addition of
99mTc-pertechnetate to a kit and heating. The 99mTc
tricarbonyl was then incubated with J591(scFv), resulting
in a radiochemical yield of 85–100%. At low protein
concentrations, the radiochemical yield increased during
incubation at 37°C up to 60 min, after which there was no
further increase. For high concentrations of J591(scFv),
the time of incubation had no effect on the radiolabelling
yield. A high NaCl concentration (500 mmol/l) modestly
increased the radiolabelling yield as we have reported
previously [20].
A final radiochemical purity of more than 99% could be
achieved after a gel filtration purification step in which a
Sephadex G-25 column removed any free pertechnetate
or tricarbonyl from the reaction mixture. This was parti-
cularly important for the serum stability experiments,
although there was some loss of radiolabelled compound
Fig. 2
Effect of NaCl concentration (140 or 500 mmol/l) on the labelling
efficiency of J591(scFv) (18 or 36 µmol/l) with 99mTc tricarbonyl. Each
data point is mean±SD for three measurements.
Fig. 3
Binding of 99mTc-J591(scFv) to PC3LN3 parental and PC3LN3-PSMA
overexpressing cell lines. Each data point is mean ±SD for three
measurements.
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on the column (recovery ∼ 80%). J591(scFv) was radio-
chemically stable in serum, with no change in the spe-
ciation of 99mTc over 24 h.
Cell-binding experiments were carried out using nega-
tive and PSMA-positive PCa cell lines. In addition to
specific binding to the receptor, nonspecific binding can
also occur because of hydrophobic and ionic interactions
with other sites on the cell surface, and it is important to
identify the contribution of specific and nonspecific
binding towards the total binding observed. Nonspecific
binding was measured using the negative cell line.
Measurement of the binding of J591(scFv) using
99mTc-J591(scFv) showed specific, saturable binding to
the PC3LN3-PSMA cell line with an EC50 value of
3.7 nmol/l, whereas only nonspecific binding was
observed in the PC3LN3 cell line (Fig. 3). Although this
does not provide an EC50 or an affinity value for
99mTc-J591(scFv) itself, it shows that 99mTc-J591(scFv)
binds specifically to PC3LN3-PSMA cells in a qualita-
tively similar manner to J591(scFv).
In parallel with this work, we have been evaluating the
potential utility of a diabody (MWt: 54 kDa) generated
from J591 [22]. It was labelled with 99mTc tricarbonyl in a
manner similar to the present work and at a similar spe-
cific activity. Specific binding of the diabody to a PSMA
overexpressing variant of the DU145 cell line was found,
with an IC50 of 5 nmol/l, very similar to the value
observed in the present work. The 99mTc-labelled dia-
body was evaluated in SCID beige mice bearing
DU145-PMSA xenografts with SPECT imaging, fol-
lowed by biodistribution studies. Blood pool clearance
was somewhat slow and tumours were not visualised until
4 h after injection, with optimal contrast at 8 h, at which
time the tumour/blood ratio was 8 and the tumour/muscle
ratio was 17 [22]. This indicates the feasibility of the
approach, but suggests that the scFv described in the
present work might be more suitable as scFv fragments
typically show more rapid blood clearance than a diabody.
Conclusion
J591(scFv) can be radiolabelled with 99mTc tricarbonyl
conveniently and efficiently. In these small-scale studies,
the maximum specific activity achieved was 7MBq/μg.
The labelled product was stable in serum. It showed
selective, saturable binding to PSMA-positive cells
compared with PSMA-negative cells. This potential
radiotracer warrants in-vivo evaluation in PCa xenograft
models.
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